They will need some time still...but...
"CDKI-73 is currently being investigated in Phase 2 clinical trials in patients with relapsed and therapy-resistant acute myeloid leukaemia, an aggressive blood cancer." Which means that at least we would not have to wait for a phase 1 to tell us the therapeutic dosage
It targets CKD9, that is expressed by tumor cells, including prostate:
They seem to have some success with ovarian cancers and in combination with Parp inhibitors. We’ll keep our fingers crossed with CDKI-73 phase 2 trials. Keep the positivity coming! The more shots on goal against PCa we have the better.
This latest story of CDKI-73 has received a lot of traction in Aussie media. While it is looking good at present, it will probably be a couple of years before the real value will be known and then another coupe of years more before it’s available. I hope I’m wrong but that seems to be the norm with all of these promising new treatments.
Why they can’t expedite these trials like they did for Covid is beyond me. Probably has something to do with costs. 😩
Oh, g'day mate! Are you from Oz? Then I am sure you can save me! 😀
I wish I could save every man on this forum and be a source of strength, hope and encouragement to all the family members who have been caught up with this issue. But alas I’m just another sufferer who has a very supportive family and a network of friends and a strong conviction in my God.
My message to everyone is to try to be as positive and upbeat as you can. Positivity is one of your best tools for fighting this disease.
God bless each of you and your families.
Keep up the good work, please.
Your information is always informative and appreciated.
Thank you for all your effort and time you put into this forum.
All the Best to you, God Bless
AMG 212 Phase 1 study shows potential.
PYLARIFY diagnostic could not find prostate cancer cells, then a surprise!
LU-177 as a first line treatment in castration resistant non netastatic prostate cancer
FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancernew trial for mCRPCa: ²²⁵Ac-rhPSMA-10.1 actinium
